4.8 Article

Four distinct trajectories of tau deposition identified in Alzheimer's disease

期刊

NATURE MEDICINE
卷 27, 期 5, 页码 871-+

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41591-021-01309-6

关键词

-

资金

  1. government of Canada through a tri-council Vanier Canada Graduate Doctoral fellowship from the McGill Centre for Integrative Neuroscience and the Healthy Brains, Healthy Lives initiative
  2. National Institutes of Health (NIH) [T32MH019112]
  3. Medical Research Council Skills Development Fellowship [MR/T027800/1]
  4. UK Research and Innovation Future Leaders Fellow [MR/S03546X/1]
  5. UK National Institute for Health Research University College London Hospitals Biomedical Research Centre
  6. Engineering and Physical Sciences Research Council [EP/M020533/1]
  7. Miguel Servet program [CP19/00031]
  8. Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional [PI20/00613]
  9. NIH [K99AG065501]
  10. European Union's Horizon 2020 research and innovation programme [666992]
  11. Swedish Research Council [2016-00906]
  12. Knut and Alice Wallenberg Foundation [2017-0383]
  13. Marianne and Marcus Wallenberg Foundation [2015.0125]
  14. Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University
  15. Swedish Alzheimer's Foundation [AF-939932]
  16. Swedish Brain Foundation [FO2019-0326]
  17. Swedish Parkinson Foundation [1280/20]
  18. Skane University Hospital Foundation [2020-O000028]
  19. Regionalt Forskningsstod [2020-0314]
  20. Swedish Federal Government under the ALF agreement [2018-Projekt0279]
  21. Basic Science Research Program through the National Research Foundation of Korea - Ministry of Education [NRF2018R1D1A1B07049386, NRF2020R1F1A1076154]
  22. Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health and Welfare, Republic of Korea [HI18C1159]
  23. National Institute on Aging (NIA) [R01 AG045611, P50 AG23501, P01 AG019724]
  24. GE Healthcare
  25. ADNI (NIH) [U01 AG024904]
  26. Department of Defense ADNI [W81XWH-12-2-0012]
  27. NIA
  28. National Institute of Biomedical Imaging and Bioengineering
  29. AbbVie
  30. Alzheimer's Association
  31. Alzheimer's Drug Discovery Foundation
  32. Araclon Biotech
  33. Bioclinica
  34. Biogen
  35. Bristol Myers Squibb
  36. CereSpir
  37. Cogstate
  38. Eisai
  39. Elan Pharmaceuticals
  40. Eli Lilly and Company
  41. EUROIMMUN
  42. F. Hoffmann-La Roche
  43. Genentech
  44. Fujirebio
  45. IXICO
  46. Janssen Alzheimer Immunotherapy Research Development
  47. Johnson & Johnson Pharmaceutical Research Development
  48. Lumosity
  49. Lundbeck
  50. Merck
  51. Meso Scale Diagnostics
  52. NeuroRx Research
  53. Neurotrack Technologies
  54. Novartis Pharmaceuticals Corporation
  55. Pfizer
  56. Piramal Imaging
  57. Servier
  58. Takeda Pharmaceutical Company
  59. Transition Therapeutics
  60. Canadian Institutes of Health Research
  61. MRC [UKDRI-1001] Funding Source: UKRI

向作者/读者索取更多资源

By using an unbiased subtyping algorithm, the study systematically characterized longitudinal tau variability in human Alzheimer's disease, identifying four trajectories of tau deposition with distinct clinical features. The results suggest that variation in tau pathology is common and systematic, potentially necessitating a re-examination of the notion of 'typical AD' and a revisiting of tau pathological staging.
Systematic characterization of longitudinal tau variability in human Alzheimer's disease using an unbiased subtyping algorithm reveals four trajectories of tau deposition with distinct clinical features. Alzheimer's disease (AD) is characterized by the spread of tau pathology throughout the cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals, although recent work has demonstrated substantial variability in the population with AD. Using tau-positron emission tomography scans from 1,612 individuals, we identified 4 distinct spatiotemporal trajectories of tau pathology, ranging in prevalence from 18 to 33%. We replicated previously described limbic-predominant and medial temporal lobe-sparing patterns, while also discovering posterior and lateral temporal patterns resembling atypical clinical variants of AD. These 'subtypes' were stable during longitudinal follow-up and were replicated in a separate sample using a different radiotracer. The subtypes presented with distinct demographic and cognitive profiles and differing longitudinal outcomes. Additionally, network diffusion models implied that pathology originates and spreads through distinct corticolimbic networks in the different subtypes. Together, our results suggest that variation in tau pathology is common and systematic, perhaps warranting a re-examination of the notion of 'typical AD' and a revisiting of tau pathological staging.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据